Xu Lu, Xie Tian, Shen Tao, Zhang Tianfeng
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
Medicine (Baltimore). 2019 Sep;98(38):e17191. doi: 10.1097/MD.0000000000017191.
Primary dysmenorrhea (PD), the most common gynecological diseases, seriously affects women's life and work; however, without more effective treatment. Chinese herbal medicine (CHM) has been widely used for relieving dysmenorrheic pain in patients with PD. To assess the effectiveness and safety of CHM in patients with PD, a systematic review and meta-analysis of current published evidence regarding CHM as treatment for PD would be conducted in this study.
Literatures related to CHM for PD from the establishment of the database to June 2019 will be retrieved from the following databases: MEDLINE, EMBACE, Wed of Science and Cochrane Central Register of Controlled Trials, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, and Wanfang Database. There are no language restrictions for retrieving literature. Eligible randomized clinical trials (RCTs) evaluating the effectiveness and safety of CHM in PD patients will be put in the study including outcomes of pain intensity, clinical effectiveness rate, quality of life, and adverse events. By scanning the titles, abstracts and full texts, 2 reviewers will independently select studies, extract data, and assess the quality of study. Meta-analysis of RCTs will be conducted using Review Manager 5.1 software. The results will be presented as risk ratio for dichotomous data, and standardized or weighted mean difference for continuous data.
This study will provide high-quality available evidence for the treatment of PD with CHM based on pain, clinical efficacy, quality of life, and adverse events.
The systematic review willto evaluate the efficacy of CHM in treating PD and provide evidence for clinicians.
CRD42019121185.
原发性痛经（PD）是最常见的妇科疾病，严重影响女性的生活和工作；然而，目前尚无更有效的治疗方法。中药（CHM）已被广泛用于缓解PD患者的痛经。为评估CHM治疗PD患者的有效性和安全性，本研究将对目前已发表的有关CHM治疗PD的证据进行系统评价和荟萃分析。
从以下数据库检索自建库至2019年6月与CHM治疗PD相关的文献：医学文献数据库（MEDLINE）、荷兰医学文摘数据库（EMBASE）、科学网（Web of Science）和考克兰系统评价数据库（Cochrane Central Register of Controlled Trials）、中国生物医学文献数据库、中国知网和万方数据库。检索文献无语言限制。符合条件的评估CHM治疗PD患者有效性和安全性的随机临床试验（RCT）将纳入本研究，包括疼痛强度、临床有效率、生活质量和不良事件等结局指标。通过浏览标题、摘要和全文，两名研究者将独立选择研究、提取数据并评估研究质量。将使用RevMan 5.1软件对RCT进行荟萃分析。结果将以二分类数据的风险比和连续数据的标准化或加权均数差表示。
本研究将基于疼痛、临床疗效、生活质量和不良事件，为CHM治疗PD提供高质量的现有证据。
该系统评价将评估CHM治疗PD的疗效，并为临床医生提供证据。
CRD42019121185。
Zotero 插件